These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 17126957)
21. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835 [TBL] [Abstract][Full Text] [Related]
23. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Imbach P; Kühne T; Müller D; Berchtold W; Zimmerman S; Elalfy M; Buchanan GR Pediatr Blood Cancer; 2006 Mar; 46(3):351-6. PubMed ID: 16086422 [TBL] [Abstract][Full Text] [Related]
24. Acute ITP due to insect bite: report of 2 cases. Akbayram S; Akgun C; Dogan M; Caksen H; Oner AF Clin Appl Thromb Hemost; 2011 Aug; 17(4):408-9. PubMed ID: 20460348 [TBL] [Abstract][Full Text] [Related]
25. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003. Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK; Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204 [TBL] [Abstract][Full Text] [Related]
26. Virus-associated immune thrombocytopenic purpura in childhood. Yenicesu I; Yetgin S; Ozyürek E; Aslan D Pediatr Hematol Oncol; 2002 Sep; 19(6):433-7. PubMed ID: 12186367 [TBL] [Abstract][Full Text] [Related]
27. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201 [TBL] [Abstract][Full Text] [Related]
28. A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence? Mantadakis E; Farmaki E; Thomaidis S; Tsalkidis A; Chatzimichael A J Pediatr Hematol Oncol; 2010 Aug; 32(6):e227-9. PubMed ID: 20539239 [TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P; Lim FS; Han HH; Willems P Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370 [TBL] [Abstract][Full Text] [Related]
30. [Acute thrombocytopenic purpura following rubella vaccination]. Yamamoto T; Kino T; Yagi K; Miyata H; Yoshioka K Rinsho Ketsueki; 1996 Nov; 37(11):1328-30. PubMed ID: 8960672 [TBL] [Abstract][Full Text] [Related]
38. [Management of autoimmune thrombocytopenic purpura: a prospective study of 147 children from the regional network RHémaP]. Le Meignen M; Mossler P; Mates M; Mathey C; Hass A; Monpoux F; Faverge B; Fortier G; Nguyen J; Belahbib L; Coache C; Chamoulli JM; Moulène E; Sirvent N; Michel G; Chambost H Arch Pediatr; 2008 Sep; 15(9):1398-406. PubMed ID: 18676127 [TBL] [Abstract][Full Text] [Related]
39. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517 [TBL] [Abstract][Full Text] [Related]
40. Thrombocytopenic purpura following vaccination in early childhood: experience of a medical center in the past 2 decades. Hsieh YL; Lin LH J Chin Med Assoc; 2010 Dec; 73(12):634-7. PubMed ID: 21145511 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]